WO1997048417A1 - Vaccine to prevent streptococcal endocarditis - Google Patents
Vaccine to prevent streptococcal endocarditis Download PDFInfo
- Publication number
- WO1997048417A1 WO1997048417A1 PCT/US1997/011329 US9711329W WO9748417A1 WO 1997048417 A1 WO1997048417 A1 WO 1997048417A1 US 9711329 W US9711329 W US 9711329W WO 9748417 A1 WO9748417 A1 WO 9748417A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fima
- endocarditis
- parasanguis
- protein
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 37
- 206010073742 Streptococcal endocarditis Diseases 0.000 title description 4
- 101000986239 Streptococcus parasanguinis Manganese ABC transporter substrate-binding lipoprotein Proteins 0.000 claims abstract description 109
- 206010014665 endocarditis Diseases 0.000 claims abstract description 69
- 241000193991 Streptococcus parasanguinis Species 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims description 27
- 208000031729 Bacteremia Diseases 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 3
- 241001312524 Streptococcus viridans Species 0.000 abstract description 17
- 230000004224 protection Effects 0.000 abstract description 14
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 48
- 101150043770 fimA gene Proteins 0.000 description 43
- 101150014100 pilA gene Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 28
- 241000700159 Rattus Species 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 23
- 239000012634 fragment Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 229950003499 fibrin Drugs 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 14
- 238000002649 immunization Methods 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 241000194019 Streptococcus mutans Species 0.000 description 10
- 201000007119 infective endocarditis Diseases 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000194017 Streptococcus Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 241000194024 Streptococcus salivarius Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000003709 heart valve Anatomy 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011552 rat model Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 241001134658 Streptococcus mitis Species 0.000 description 4
- 241000194023 Streptococcus sanguinis Species 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 210000004201 immune sera Anatomy 0.000 description 4
- 229940042743 immune sera Drugs 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010014666 Endocarditis bacterial Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000011965 Lipoprotein Receptors Human genes 0.000 description 3
- 108010061306 Lipoprotein Receptors Proteins 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000009361 bacterial endocarditis Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014684 Endocarditis staphylococcal Diseases 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000701988 Escherichia virus T5 Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010051018 Streptococcal bacteraemia Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 241000201856 Abiotrophia defectiva Species 0.000 description 1
- 101100130893 Alkalihalobacillus halodurans (strain ATCC BAA-125 / DSM 18197 / FERM 7344 / JCM 9153 / C-125) mntA gene Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 101100084597 Dictyostelium discoideum pspA gene Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010042889 Inulosucrase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 241001149563 Streptococcus mutans ATCC 25175 Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001174 endocardium Anatomy 0.000 description 1
- 230000009843 endothelial lesion Effects 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 101150011498 lad gene Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 101150043479 psaA gene Proteins 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the invention is directed to vaccines and, more particularly, to a vaccine for the prevention of endocarditis.
- Infective endocarditis is a serious endovascular infection causing substantial morbidity and mortality despite medical and surgical advances over the last several decades (11,18,38). In the United States, there are 30-40 cases per million a year (1,6, 1 1). In Europe, the annual incidence of disease ranges from 14-24 cases per million (19,25,41). Epidemiologic surveys reveal that the incidence of endocarditis increases significantly with age and that in developed countries with a growing population of elderly people, endocarditis is a disease of increasing medical importance (18, 19,25,41). Native valve endocarditis occurs predominantly in patients with predisposing heart lesions.
- High and moderate risk patients are those with a history of infective endocarditis, prosthetic heart valves, surgical systemic-pulmonary shunts, congenital cardiac malfunctions, rheumatic valvular disease, mitral valve prolapse, and hyperthropic cardiomyopathy (10).
- valve disease daily low-grade bacteremia which occurs during eating and tooth brushing affords the opportunity for circulating bacteria to attach to the abnormal endocardium (21).
- Other high-risk patient populations include those without preexisting valve lesions who have a history of recent exposure to invasive dental, upper respiratory, gastrointestinal, and genitourinary diagnostic and surgical procedures (22,31,37)
- FimA is an important virulence determinant in S. parasanguis endocarditis and is implicated in promoting bacterial adherence to fibrin in vegetations (7).
- This invention contemplates a composition of matter which takes the form of a protein found on the surface of many streptococcal species present in the human mouth. This protein, in purified form, can be administered as a vaccine and confers protection against endocarditis.
- Streptotoccus parasanguis the material, called FimA, is found on many streptococci and enterococci bacteria. Protection in animals has been demonstrated using a rodent model system, which reliably mimics human endocarditis
- the S. parasanguis FimA protein was over produced and purified using the Qiagen pQE30 plasmid expression system Purified FimA was used to investigate its usefulness as a vaccine in a rat model of endocarditis
- the vaccination regimen was as follows Nine-week old male Sprague-Dawley rats were given an initial dose of 100 ⁇ g of purified FimA emulsified in Freund's Complete Adjuvant. The antigen preparation was given in an area of the animal's flank in six intradermal injections The same site was used for a booster dose of 100 ⁇ g of protein in Incomplete Freund's Adjuvant three weeks later.
- this invention includes a primary protective vaccine against endocarditis, a method for preventing endocarditis, and formulations useful in protecting against endocarditis and methods for producing the vaccine formulations.
- the vaccine of this invention may also be used to prevent streptococcal bacteremia, a clinical condition seen increasingly in immuno- compromised patients.
- the FimA would be provided to an immuno-compromised patient (e.g., a bone marrow transplant patient) by intramuscular injection or other route prior to high dose chemotherapy or radiation therapy, and would elicit opsonic antibodies to invading streptococci in the patient's blood stream, thus enhancing clearance of these infectants.
- Figure 1 is a schematic diagram showing the cloning of fimA into the pQE30 expression vector fimA DNA from pVT781 was amplified by PCR Primers were designed to modify the ends of the fimA DNA for subclomng as an Sphl-Hindlll fragment at the multicloning site of the pQE30 vector
- This expression vector contained a phage T5 promoter and two lac operator sequences
- the E coh host cell has multiple copies of the plasmid pREP4 which carries the lad gene ensu ⁇ ng tight regulation of protein expression
- the construct pVA2341 has the six histidine residue affinity tag 5' to fimA
- Figure 2 is a photograph of a protein analysis gel of purified recombinant FimA.
- Figures 4a-c are bar graphs showing the adherence properties of S parasanguis strains Bacterial adherence to platelet-fib ⁇ n matrix and adherence of S parasanguis FW213 incubated with adsorbed sera to platelet-fibrin
- FIG. 4C shows the results when S parasanguis FW213 incubated in rabbit serum adsorbed with VT930 was exposed to a platelet-fibrin mat ⁇ x
- Incubation of S parasanguis FW213 with anti-FimA sera adsorbed with VT930 blocked adherence of S parasanguis FW213 to the platelet-fibrin matrix (0 34%) but no such blocking effect was observed by incubation with adsorbed preimmune sera (5 04%) (p ⁇ O OO1)
- Figure 5 are nucleotide sequences (SEQ LD Nos 1-10) showing the alignment of portions of the nucleotide sequences of fimA (SEQ ID No 1 and SEQ LD No. 6) and its homologs derived from the GCG program Pileup
- the primer pair in bold letters and identified with brackets 10 and 12 corresponds to nucleotides 151-173 and 868-893 of fimA and represents conserved regions in the lipoprotein receptor antigen (Lral) family
- the average size of the genes in this family is 930 bp in length
- the primers are 5' GCTGGGGATAAGATCGAGCTCCACAG 3' (SEQ ID No 1 1), and
- Figures 6a and 6b are photographs of gels showing the detection of fimA homologs.
- Figure 6a shows a Southern blot of EcoR] -digested genomic DNA from streptococcal strains using fimA DNA as a probe Lanes IJimA DNA, 2, S mutans ATCC 25175, 3, S bovis ATCC 43144,
- Figure 6b shows 0 8% gel electrophoresis of PCR amplified genomic DNA from various streptococcal strains
- the primer pair corresponds to nucleotides of fimA described in Figure 5 Lanes: 1, molecular size markers, 2, S parasanguis FW213; 3, S mutans ATCC 25175, 4, S.
- FimA-like proteins in clinical isolates Clinical isolates from bacteremic patients were grown anaerobically in 50 ml of BHI broth for 48 hours at 37°C. Bacterial cells were disrupted using a MiniBeadTM beater. Protein samples were separated by 10% TrisGlycine SDS PAGE and electrotransferred to a nitrocellulose membrane and probed with polyclonal anti-FimA. The bound antibodies were visualized by addition of anti-rabbit
- This invention provides a different approach and describes the first and only primary protective vaccine against endocarditis.
- the vaccine could be provided by parenteral (e.g., intravenous, intramuscular, intradermal, subcutaneous), oral, sublingual, transdermal and other routes of administration well known in the art.
- parenteral e.g., intravenous, intramuscular, intradermal, subcutaneous
- the preferred mode of delivery is parenteral.
- the FimA could be provided in combination with carrier fluids (e.g , water based (saline, etc ) or oil based or emulsions), stabilizing agents, preservatives (e.g., parabens, benzalkonium chloride (BAK), etc.), and the like as appropriate to the delivery route.
- carrier may be a solid lactose based material
- FimA protein of the vaccine should be provided in quantities sufficient to confer protection by the patient's body raising antibodies to FimA, and could be provided as a bolus dose with follow up boosters, or a single bolus dose, or according to other dosing regimens depending on the patient and formulation of the vaccine.
- FimA protein or fragment thereof in the vaccine can be isolated from a variety of streptococci or enteroccoci, or, as discussed in detail below, be recombinantly produced in a bacterial, mammalian or plant cell host, or be manufactured by other means.
- the gene for FimA can be isolated and transferred to a plasmid for subsequent production in an E. coli host; however, it will be apparent to those of skill in the art that the gene might be transferred and expressed in and retrieved from a wide variety of different cell systems or from a living animal or plant.
- FimA also might be accomplished so as to render FimA or its subsequence peptides as fusion proteins. Fusion to other proteins to increase the immunogenicity of FimA and/or to increase its stability would be desired outcomes of such fusion protein construction.
- the source of the FimA protein should not limit the protein's effectiveness as a vaccine against endocarditis or bacteremia derived from either viridans streptococci and enterococci.
- a vaccine could take the form of a mixture of FimA proteins derived from a mixture of viridans streptococci and enterococci. In the case of fragments of the FimA protein being used as the vaccine, enough of the protein should be present such that immunization causes antibody-mediated protection.
- Bacterial strains, plasmids and media Wild type S. parasanguis FW213, its isogt ⁇ c fimA insertion mutant, VT930 (does not express FimA protein), and E. coli, VT786, a recombinant FimA producing strain, have been described previously (13,14).
- the Ml 5 E. coli host strain, pQE30 expression vector, and pREP4 repressor plasmid were from the Qiaexpress system (Qiagen Inc. Chatsworth, CA). Streptococcal strains were grown anaerobically (10% CO 2 , 10% H 2 , 80% N 2 ) at 37 °C in brain heart infusion
- BHI Bacterial cultures were stored at 70 °C in BHI with 30% glycerol.
- Plasmid DNA was isolated using the Qiagen ® plasmid purification protocol. Agarose gel electrophoresis protocols were those of Sambrook et al. (28). Restriction endonucleases were purchased from Bethesda Research Laboratories, Inc. (Gaithersburg, MD) and enzymatic digestions were performed according to the manufacturer's directions. Preparation of Streptococcus chromosomal DNA was as described previously (35).
- Oligonucleotides used to PCR amplify fimA were synthesized by Bio-Synthesis, IncorporatedTM (Lewisville, TX).
- the oligonucleotide sequences corresponding to fimA nucleotides 1-17 and 916-930 were: 5' ACATGCATGCAAAAAAATCGCTTC 3' (SEQ ID No. 13) and 5' CCCAAGCTTACTGACTCAATCC 3' (SEQ ID No. 14).
- the primers were designed so that the ends of the fimA DNA could be subcioned as an Sphl-Hmdlll fragment into a pQE expression vector
- the multicloning region of pQE30 contains restriction endonuclease sites for B ⁇ mBI, Sphl, S ⁇ cl, Kpril, Sm ⁇ VXm ⁇ l, Sail, Pstl and Hindlll. Integration into pQE30 using Sphl and PC17US97/11329
- Hmdlll directional cloning resulted in a six histidine residue extension at the amino terminus of fimA.
- the expression construct was transformed into the Ml 5 host strain carrying the plasmid pREP4 which car ⁇ es the lacl gene Transformants were selected on LB agar plates containing ampicillin and kanamycin and screened for correct insertion of the fimA gene by DNA restriction endonuclease cleavage analysis.
- the nucleotide sequence of the subcioned DNA in the construct which expressed FimA was confirmed by DNA sequencing. Automated sequencing reactions were performed by the Sanger-based dideoxy chain termination method (PRISMTM Ready Reaction DyeDeoxyTM Terminator
- Antisera directed against FimA were prepared by subdermal injection of female New Zealand White rabbits at the back of the neck with 0 5 mg FimA suspended in 0 5 ml phosphate buffered saline (PBS) (pH 7 4) and emulsified in an equal volume of complete Freund's adjuvant (CFA) A booster injection of 0 5 mg FimA in incomplete
- EIA Enzyme immunoassay
- EIA plates (Costar, Cambridge, MA) were coated with 10 ⁇ g/ml FimA in carbonate-bicarbonate buffer (pH 9.5) and blocked with washing buffer. Serum from each animal was serially diluted in PBS. The optimal dilutions for the secondary antibodies were determined in titration assays. The peroxidase-conjugated goat anti-rabbit antibody (Sigma) or peroxidase-conjugated mouse anti-rat antibody (Jackson Immunoresearch laboratories, Inc., West Grove, PA) was detected by TMBlue substrate (TSI Center for Diagnostics Products, Milford, MA) and color development was stopped with IN H 2 S0 4 . Plates were read with a 700 MR microplate reader (Dynatech Laboratories, Inc., Chantilly, VA).
- Antibody titers were expressed as the reciprocal of the highest serum dilution with A 450 of ⁇ 0.10 10 min after addition of substrate.
- the immunization dose per Sprague-Dawley rat contained 100 ⁇ g of FimA in CFA. The dose was given by intradermal injection at 6 different sites in a shaved area of the rat's right flank. The same area was used for a booster dose of 100 ⁇ g of protein in IFA three weeks later.
- catheterization and bacterial challenge as described below were performed six weeks after the initial immunization.
- nonimmunized and immunized rats were exsanguinated by cardiac puncture two weeks after the booster dose to determine serum antibody titers.
- Rat model of endocarditis The rat model of endocarditis employed in this study was as described by Munro and Macrina (24). Approval for animal use was obtained from the VCU IACUC (protocol no. 9410-2082) prior to initiation of experiments. Male Sprague-Dawley rats (Harlan, Indianapolis, Ind.) were challenged with 1 X 10 7 bacteria 1-5 days after cardiac catheterization. The significance of differences between the numbers of Streptococcus infected vegetations obtained from immunized and non-immunized rats was calculated by Fisher's exact test.
- Platelet-fibrin adherence assay Methods adapted from Scheld, et al (32) and Munro and Macrina (24) were used.
- an overnight culture of streptococci in BHI was diluted 1 : 10 in fresh BHI and was grown anaerobically to an optical density at 660 nm of ⁇ 0.6.
- Bacteria were washed in PBS, sonicated, and diluted to yield 1 X 10 8 cells per ml. In some experiments, these bacteria then were incubated with either preimmune or immune sera for 30 min at 37 °C.
- the plates were incubated anaerobically at 37 °C for 48 h
- the percent adherence was calculated as- (number of colony forming units recovered/number of cells introduced onto the platelet-fibrin plate) X 100.
- Statistical analysis was calculated by Student's / test.
- the DNA was immobilized on the membrane by ultraviolet irradiation in a model 2400 UV StratalinkerTM (Stratagene, La Jolla, CA). Random-primed radioactive labeling of full length fimA probe was generated by using Prime-a-Gene ® (Promega Corp.).
- the nitrocellulose membrane was incubated for 1 h at 42° C in a prehybridization buffer consisting of 5X SSPE (0.75M NaCl, 5 mM EDTA, 0.05 MM NaH 2 PO 4 ), 5X Denhardt's reagent, 100 ⁇ g/ml salmon sperm DNA and 25% formamide.
- Hybridization with the randomly labeled probe was carried out at 42° C for 18 h in a solution of 5X SSPE, IX Denhardt's reagent, 100 ⁇ g/ml salmon sperm DNA, and 25 % formamide. After hybridization, the membrane was washed twice (15 min each) in 2X SSPE with 0. 1% SDS and then washed twice (15 min each) in 0. IX SSPE with 0.1% SDS at room temperature to remove unbound probe. Prehybridization, hybridization and washing steps were performed in a Savant Gene RollerTM hybridization oven (Savant Instruments, Inc., Holbrook, NY). The membrane was exposed to ReflectionTM autoradiography film (Du Pont-NENG ® Research Products,
- Oligonucleotides were designed to amplify fimA homologs from Streptococcus spp.
- the synthetic oligonucleotides 5' GCTGGGGATAAGATCGAGCTCCACAG 3' (SEQ ID No 1 1) (nucleotides 151 to 173 in Figure 5) and 5' TTCATCATGCTGTAGTAGCTATCGCC 3' (SEQ ID No. 12) (complementary to nucleotides 868 to 893) derived from fimA related sequences found in well-conserved regions of the lipoprotein receptor antigen I (Lral) family of genes were used as primers to amplify by PCR
- GenAmp 9 PCR core reagents Perkin Elmer Corp., Norwalk, CT
- reactions were carried out for 28 cycles (94 °C for 30 sec, 55 °C for 20 sec, and 72°C for 45 sec) with an automated thermal cycler, GeneAmp PCR System 9600 (Perkin Elmer Corp )
- the reaction products were analyzed by 0.8% agarose gel electrophoresis.
- the cells were disrupted in a Mini-Bead Beater homogenizer (Biospec Products) for 2 minutes. Beads and cellular debris were removed by centrifugation at 12,000 X g for 5 minutes to obtain a clear lysate The lysates were kept at 4°C until protein analyses were performed
- FimA Overexpression and purification of FimA. It has been demonstrated that a fimA insertion mutant, VT930, had significantly reduced virulence in the rat endocarditis model compared to wild-type S parasanguis FW213 It was deduced from in vitro experimental data that virulence was associated with adherence of FimA to fibrin. Recombinant FimA was made using the System for further in vivo and in vitro studies. The cloning of fimA into a pQE expression vector was done as described in Materials and Methods (Fig. 1). Oligonucleotide primers were synthesized to amplify fimA by PCR. The DNA product was subcioned into a pQE30 vector.
- the expression vector contained a phage T5 promoter and two l ⁇ c operator sequences thereby increasing the probability of l ⁇ c repressor binding and ensuring effective repression of the T5 promoter.
- This plasmid had a synthetic ribosomal binding site for more efficient translation and two transcriptional terminators, t 0 from phage lambda and t j from the rrnB operon of E. coli, which prevented read-through transcription thus stabilizing the expression construct.
- the six consecutive histidine residue tag and the start codon (ATG) were upstream of the polylinker sequence.
- the E. coli Ml 5 host expression strain carried the pREP4 plasmid.
- the nucleotide sequence of the subcioned DNA in the construct was analyzed and confirmed.
- the 6X histidine residue served as a convenient affinity tag for purification of FimA from crude E. coli lysates under native conditions.
- the Ni-NTA resin metal chelate adsorbent allowed for separation of most contaminating proteins. Other contaminants were subsequently removed by gel filtration.
- FimA with the 6X histidine tag migrated more slowly and appeared larger than its expected size of 36kDa on SDS-PAGE gel. Presumed lower molecular weight degradation products were apparent. Based on molecular size analysis, native FimA appeared in monomeric and dimeric forms (see arrows to right of Fig. 2)
- the rat model is considered predictive of human endocarditis infection because rat cardiovascular anatomy is very similar to that of the human, and the course and outcome of infection are clinically similar. Infected vegetations from rats and humans are visually indistinguishable microscopically.
- the S. mutans data represents pooled data from infections using three clinical isolates of this species, all with identical genotypic HaeIII-DNA restriction fragment patterns. All of the p values were highly significant indicating protection conferred by the FimA vaccine. Thus, these data indicate FimA is a virulence factor in these other strains as has been demonstrated in S. parasanguis. While the data do not suggest the requirement, the vaccine may include several different FimA proteins from several different sources.
- the FimA used in the vaccine should be of a sufficient quantity, and of a sufficient size in the case of a FimA fragment, to allow a patient's body to raise antibodies against the FimA in an immune response
- Figure 3 shows that the antibody titers raised in an effective vaccine could be 1 : 10,000 to 1 100,000.
- Platelet-fibrin matrices were prepared and the percent adherence of streptococci was determined The results of adherence and immune blockade assays from three replicate experiments, each of which were performed in triplicate, are illustrated in Figure 4a-c. The ability of wild type S.
- fimA homologs among viridans streptococci and enterococci.
- fimA is one of five known genes which encode proteins belonging to the Lral family of adhesins (20)
- the presence of fimA homologs among viridans streptococci and enterococci which commonly cause native valve endocarditis were determined to explore the feasibility of utilizing FimA as a broadly protective vaccine against streptococcal endocarditis
- Southern blot analysis of streptococcal genomic DNA digested with EcoRI and probed with full length fimA DNA showed the presence of reactive fragments in six of seven streptococci tested (Fig 6A) Hybridizing fragments which co-migrated -with fimA were found with S mutans ATCC 25175, S orahs ATCC 10557, and S salivarius ATCC 7073 Less well-hybridizing fragments of differing molecular weights were observed with S salivarius, and S anginosus ATCC 27823 The
- FimA is a protein found on the cell surface of streptococci and enterococci and belongs to the lipoprotein receptor adhesin family (5,16,29)
- Several species of viridans streptococci and enterococci that cause endocarditis are known to have genes that encode for these proteins According to Mandell et al. (Principles and Practice of Infectious Diseases 4 th edition, Churchill Livingstone, NY, 1995, P 753) streptococci account for 60-80% of the cases of endocarditis. The viridans streptococci alone account for 30-40% of all cases.
- Polyclonal antisera raised against FimA from S. parasanguis were used to evaluate whether a related antigen is present in other streptococci and enterococci. Blood isolates from clinical patients were screened by immunoblot (Western blot) using polyclonal antisera Table 3 shows that FimA is broadly expressed among bacteria which most frequently cause endocarditis
- FimA shall mean FimA and FimA like proteins, and fragments or fusion proteins thereof, which are derived from any species known to express these proteins
- EfaA and FimA have been implicated in endocarditis pathogenesis (3,5, 16,29)
- the Qiaexpress System can be used for expression and purification of recombinant FimA in E coli As illustrated in Figure 2, a relatively pure preparation of native FimA was eluted from the Ni-NTA column and other nonspecific contaminants were effectively removed by gel filtration FimA monomers and dimers were evident in the Coomassie-stamed SDS PAGE gel Polymeric forms of FimA may also be produced other overexpression and renaturation protocol (26)
- FimA adhesin as a vaccine is that antibody formed against it may interfere with bacte ⁇ al adherence and thereby reduce virulence
- the pathogens are less likely to be opsonized and phagocytosed
- the data presented above shows that immunized animals were less susceptible to subsequent challenge with S parasanguis FW213 than the nonimmunized group
- the FimA from S parasanguis was protective against heterologous infectious challenge
- the vaccine of this invention may also be used to prevent streptococcal bacteremia, a clinical condition seen increasingly in lmmuno- compromised patients
- the FimA would be provided to an lmmuno-compromised patient (e g , a bone marrow transplant patient) by intramuscular injection or other route prior to high dose chemotherapy or radiation therapy, and would elicit opsonic antibodies to invading streptococci in the patient's blood stream, thus enhancing clearance of these infectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10503584A JP2000514790A (en) | 1996-06-21 | 1997-06-20 | Streptococcal endocarditis prevention vaccine |
AU35848/97A AU3584897A (en) | 1996-06-21 | 1997-06-20 | Vaccine to prevent streptococcal endocarditis |
EP97932373A EP0912193A4 (en) | 1996-06-21 | 1997-06-20 | Vaccine to prevent streptococcal endocarditis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2017496P | 1996-06-21 | 1996-06-21 | |
US60/020,174 | 1996-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997048417A1 true WO1997048417A1 (en) | 1997-12-24 |
Family
ID=21797134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/011329 WO1997048417A1 (en) | 1996-06-21 | 1997-06-20 | Vaccine to prevent streptococcal endocarditis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0912193A4 (en) |
JP (1) | JP2000514790A (en) |
AU (1) | AU3584897A (en) |
CA (1) | CA2258011A1 (en) |
WO (1) | WO1997048417A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0834568A2 (en) * | 1996-09-24 | 1998-04-08 | Smithkline Beecham Corporation | Novel saliva binding protein |
US6582706B1 (en) | 1998-12-21 | 2003-06-24 | Medimmune, Inc. | Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS |
WO2015052630A1 (en) * | 2013-10-07 | 2015-04-16 | Uab Bioseka | Antisense oligonucleotides for prevention of atherosclerosis and cardiovascular infections |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994025598A2 (en) * | 1993-04-26 | 1994-11-10 | University Of Victoria Innovation And Development Corporation | Methods and compositions for salmonella-based vaccines |
US5422427A (en) * | 1991-09-17 | 1995-06-06 | The United States Of America As Represented By The United States Department Of Health And Human Services | Pneumococcal fimbrial protein A |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3065892A (en) * | 1991-11-14 | 1993-06-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Pneumococcal fimbrial protein a vaccines |
-
1997
- 1997-06-20 EP EP97932373A patent/EP0912193A4/en not_active Withdrawn
- 1997-06-20 JP JP10503584A patent/JP2000514790A/en active Pending
- 1997-06-20 WO PCT/US1997/011329 patent/WO1997048417A1/en not_active Application Discontinuation
- 1997-06-20 CA CA002258011A patent/CA2258011A1/en not_active Abandoned
- 1997-06-20 AU AU35848/97A patent/AU3584897A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422427A (en) * | 1991-09-17 | 1995-06-06 | The United States Of America As Represented By The United States Department Of Health And Human Services | Pneumococcal fimbrial protein A |
WO1994025598A2 (en) * | 1993-04-26 | 1994-11-10 | University Of Victoria Innovation And Development Corporation | Methods and compositions for salmonella-based vaccines |
Non-Patent Citations (3)
Title |
---|
HAUTARZT, April 1989, Vol. 40, No. 4, HAUSTEIN et al., "Die Behandlung des Chronisch-Rezidivierenden Erysipels mit Streptokkenvakzinc", pages 215-221. * |
INFECTION AND IMMUNITY, November 1989, Vol. 57, No. 11, FENNO et al., "Nucleotide Sequence Analysis of a Type 1 Fimbrial Gene of Streptococcus Sanguis FW 213", pages 3527-3533. * |
See also references of EP0912193A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0834568A2 (en) * | 1996-09-24 | 1998-04-08 | Smithkline Beecham Corporation | Novel saliva binding protein |
EP0834568A3 (en) * | 1996-09-24 | 1999-12-01 | Smithkline Beecham Corporation | Novel saliva binding protein |
US6582706B1 (en) | 1998-12-21 | 2003-06-24 | Medimmune, Inc. | Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS |
US7122194B2 (en) | 1998-12-21 | 2006-10-17 | Medimmune, Inc. | Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural motifs |
WO2015052630A1 (en) * | 2013-10-07 | 2015-04-16 | Uab Bioseka | Antisense oligonucleotides for prevention of atherosclerosis and cardiovascular infections |
Also Published As
Publication number | Publication date |
---|---|
CA2258011A1 (en) | 1997-12-24 |
JP2000514790A (en) | 2000-11-07 |
AU3584897A (en) | 1998-01-07 |
EP0912193A1 (en) | 1999-05-06 |
EP0912193A4 (en) | 2000-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Viscount et al. | Immunization with FimA protects against Streptococcus parasanguis endocarditis in rats | |
Konkel et al. | Identification and molecular cloning of a gene encoding a fibronectin‐binding protein (CadF) from Campylobacter jejuni | |
SK287456B6 (en) | Proteinase K resistant surface protein of Neisseria meningitidis | |
US20090117142A1 (en) | Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof | |
AU5682896A (en) | Streptococcal heat shock proteins members of the HSP70 family | |
EP2256205B1 (en) | Porphorymonas gingivalis polypeptides and polynucleotides | |
Spinola et al. | The conserved 18,000-molecular-weight outer membrane protein of Haemophilus ducreyi has homology to PAL | |
JP3998155B2 (en) | Vacuole-forming toxin deficient pylori and related methods | |
Franke et al. | Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs | |
DK2356135T3 (en) | IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE | |
WO1997048417A1 (en) | Vaccine to prevent streptococcal endocarditis | |
US7449310B2 (en) | Recombinant Fusobacterium necrophorum leukotoxin vaccine and preparation thereof | |
EP2391640B1 (en) | A clostridium chauvoei polypeptide, dna encoding the polypeptide and a vaccine comprising the polypeptide | |
AU2001259138A1 (en) | Recombinant fusobacterium necrophorum leukotoxin vaccine and preparation thereof | |
WO1998042842A1 (en) | A porin gene from campylobacter jejuni, related products and uses thereof | |
JP4500615B2 (en) | Novel polypeptide having protective activity against sweptococcal infection derived from serotype 18, which is another species of the genus Erichiperotricks, its gene and production method | |
Barr et al. | Ross et a1. | |
WO2004007725A9 (en) | Polypeptide of streptococcus pyogenes | |
Viscount | Pathogenesis and immunology of streptococcal endocarditis | |
Hamel et al. | Antigenic and Molecular Conservation of |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2258011 Country of ref document: CA Ref country code: CA Ref document number: 2258011 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997932373 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997932373 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997932373 Country of ref document: EP |